METHODS: We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.
RESULTS: Implants were left in situ for an average of 24 months. Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained. No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.
CONCLUSIONS: A single histrelin implant provides excellent pubertal suppression well beyond a year. Extended use of a single histrelin implant should be considered standard of care in children with CPP.
方法:我们对170例中枢性性早熟患儿进行了回顾性研究,这些患儿采用单一histrelin植入治疗超过1年。
结果:植入物在原位放置平均24个月。绝大多数患者的青春期发育消退或保持稳定,生化抑制得以维持。放置植入物的时间与植入物破裂或第二次切口等并发症之间没有相关性。
结论:一个单一的histrelin植入物提供了良好的青春期抑制超过一年。延长使用单一histrelin植入物应被视为CPP儿童的护理标准。